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Opinion
Congenital disorders of cardiac repolarization are associated 
with risk of serious arrhythmias and sudden death. The Long 
QT Syndrome (LQTS) is well-established to predispose towards 
torsades de pointes [1]. The Short QT Syndrome (SQTS) is a 
more recently discovered condition involving abbreviated 
repolarization that predisposes to atrial and ventricular 
arrhythmias and sudden death [2]. It is characterized by short 
QT intervals on the electrocardiogram, frequently with tall up-
right T waves and by a poor rate adaptation of the QT interval: 
short QT intervals persist even at slow heart rates [2-4]. Due 
to the risk of sudden death, SQTS patients are often treated 
with implantable cardioverter defi brillators (ICDs). Mutations 
to genes that encode critical components of cardiac potassium 
channels have been implicated in the syndrome: KCNH2 in 
SQT1, KCNQ1 in SQT2 and KCNJ2 in SQT3 [2-4]. Of successfully 
genotyped cases, the most prevalent mutations affect KCNH2 
[3]. KCNH2 (alternative nomenclature hERG: human-Ether-
à-go-go-Related Gene) is responsible for encoding the 
pore-forming protein of channels that mediate the cardiac 
rapid delayed rectifi er current, IKr [5]. IKr is vital for normal 
ventricular repolarization, evidenced by the fact that loss-
of-function mutations in hERG-mediated subunits underpin 
the LQT2 form of congenital Long QT Syndrome [1,5]. Gain-
of-function mutations in hERG-mediated subunits underpin 
variant 1 (SQT1) of the SQTS [2,3]. 
The gene mutations with the largest effects on hERG/
IKr channel current amplitude and kinetics in the SQTS give 
rise to an asparagine to lysine (NK) substitution (N588K) 
in the external S5-Pore linker region that contributes to 
control of the process of hERG channel inactivation [6-9]. 
The N588K mutation results in a profound positive voltage-
shift in the inactivation of the hERG/IKr channel; this in turn 
results in greater repolarizing current, timed earlier during 
ventricular action potentials [6,8,9], resulting in accelerated 
repolarization and an SQTS phenotype. hERG is a target of Class 
III antiarrhythmic drugs, including methanesulphonanilides 
such as sotalol and dofetilide and the N588K mutation was 
found signifi cantly to impair the ability of this class of drugs to 
interact with the hERG channel [6,10-12]. 
Very recently a new SQT1 mutation has been reported 
involving a serine to alanine (SA) substitution (S631A) in the 
hERG channel pore region [13]. The index patient was screened 
at the age of 6 following the sudden death of a cousin and was 
found to have a rate-corrected (QTc) QT interval below 320 
ms. She was without symptoms until experiencing syncope 
ten years later during physical exertion and then underwent 
ICD implantation [13]. Her father was asymptomatic but also 
possessed a shortened QTc interval (324 ms). Her sister also 
possessed a shortened QTc interval (340 ms) and a modest 
reduction in left ventricular ejection fraction (to 47%), but 
without other cardiac symptoms. Neither she nor the father 
underwent ICD implantation [13]. An asymptomatic brother 
did not possess a short QT interval. However, the father had 
a sister who had died suddenly at 30 and another sister with 
two sons who had died suddenly [13]. On genetic screening, the 
proband, her sister and father were found to have the S631A 
mutation, whilst her asymptomatic brother did not [13]. The 
index patient also possessed an SCN10A variant (R1869C), but 
her father did not and her mother, who did not have a short QT 
interval, did have the SCN10A variant [13]. This suggests that 
the hERG mutation and not the SCN10A variant was responsible 
for the SQTS phenotype in this family [13].
The identifi cation of the S631A hERG mutation in clinical 
SQTS is interesting in a number of respects. Although 
this recent report is the fi rst to implicate the mutation in 
clinical SQTS, the S631A mutation has long been used in 
basic science investigations to study the hERG/IKr channel’s 
P-type inactivation process [14,15]. It produces a profound 
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(>100 mV) positive shift in voltage-dependent inactivation of 
hERG current, without affecting voltage dependent activation 
[15]. Under action potential voltage clamp, S631A produced 
changes to hERG current profi le during the ventricular 
action potential [16], that are very similar to those reported 
much later for N588K [6,8,9]. It is highly likely, therefore, 
that mechanisms of proarrhythmia are also similar to those 
reported for N588K using computational modelling [17]. 
Perhaps most signifi cantly, there already exists a sizeable body 
of pharmacological literature on the S631A hERG mutation. 
For example, a study from 2000 identifi ed that the sensitivity 
of hERG to the class III antiarrhythmic drug dofetilide was 
greatly attenuated by the S631A mutation, whilst that to the 
class Ia drug quinidine was little altered [18]. Work from this 
laboratory subsequently identifi ed that a second class Ia drug, 
disopyramide, was able to block S631A hERG channels [19], 
and in a subsequent side-by-side comparison of S631A and 
N588K, we found similarly modest attenuating effects of the 
two individual mutations on the potencies of disopyramide and 
quinidine, whilst combining the 2 mutations (which produces 
a greater attenuation of inactivation) had a greater effect on 
the actions of the two drugs [12]. Unlike sotalol, quinidine is 
effective in the treatment of N588K-linked SQT1 [2,3,6,10], 
and disopyramide has some effectiveness too [20]. Given the 
preclinical pharmacological data on S631A hERG channels, it 
is reasonable cautiously to propose that both quinidine and 
disopyramide may have potential value in cases of S631A hERG 
mutation linked SQT1, delaying repolarization and prolonging 
refractoriness in this setting. In principle, these drugs could 
be of prophylactic use in patients with this mutation in whom 
ICDs were not fi tted, or as an adjunct therapy in patients with 
such devices.
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